TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

POHERDY

PERTUZUMAB-DPZB
Approved 2025-11-13
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
0
Years on Market

Details

Status
Prescription
First Approved
2025-11-13
Routes
INTRAVENOUS
Dosage Forms
INJECTABLE

Companies

SHANGHAI HENLIUS BIOTECH
Active Ingredient: PERTUZUMAB-DPZB

POHERDY Approval History

Loading approval history...

What POHERDY Treats

1 FDA approvals

Originally approved for its first indication in 2025 .

  • Other (1)
Auto-substitute OK for Perjeta

Pharmacists can substitute POHERDY for Perjeta without calling the prescriber. This is a lower-cost alternative with no clinically meaningful differences.

🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

POHERDY FDA Label Details

Pro

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: BLA761450 → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.